Dr. Evan T. Hall
Medical Oncology (Medical Oncology Physician)
825 Eastlake Ave E
Seattle, WA 98109
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 156
Licensed in Washington since 2019, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
WA license MD60928166 (first issued 2019; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Washington Medical Ctr Seattle, WA
Medical groups
- The Association of University Physicians (3,535 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 156
- Services billed
- 536
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 123 | 54 |
| Established patient office or other outpatient visit, 30-39 minutes | 96 | 61 |
| New patient office or other outpatient visit, 60-74 minutes | 31 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Cabometyx (cabozantinib s-malate) | 22 |
| Hydrocortisone Other prescribers in Seattle, WA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $445,150 in research payments for these studies, mostly to the institutions running them.
- A phase 1AB openlabel master study of PF07799544 as a singleagent and in combination with other targeted agents in participants with advanced solid tumors
Pfizer Inc. - A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06190951
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.